The FDA accepted Arvinas and Pfizer’s New Drug Application (NDA) for vepdegestrant, an oral PROTAC estrogen receptor degrader, for ER-positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer in patients previously treated with endocrine therapy. The PDUFA date is set for June 5, 2026. The NDA is based on the VERITAC-2 Phase 3 trial.
This NDA filing marks a significant step for Arvinas. It represents the first potential approval of a PROTAC protein degrader in oncology, validating the company’s platform technology and its partnership strategy with Pfizer. The acceptance sets the stage for vepdegestrant to enter a competitive breast cancer treatment landscape.
Arvinas is targeting a specific patient subset – those with ESR1 mutations – who often face limited treatment options after initial endocrine therapy and CDK 4/6 inhibitors. While the full VERITAC-2 data are awaited, the positive topline results suggest a potential advantage in progression-free survival. This focus on a genetically defined population aligns with increasing FDA emphasis on precision oncology and targeted therapies.
This NDA acceptance has important implications for both drug development and the competitive landscape. For Arvinas, it offers a path to its first commercial product, potentially establishing the company as a leader in the emerging field of targeted protein degradation. For Pfizer, it expands its oncology portfolio with a novel mechanism of action. The approval’s potential impact on research sites, particularly those specializing in breast cancer, hinges on the drug’s eventual uptake and place in treatment algorithms. Monitoring and managing patients on vepasertib could create new operational demands.
Looking ahead, several key questions remain. The full VERITAC-2 data, including overall survival and safety details, will be crucial in determining vepdegestrant’s clinical value proposition. Commercial success will depend on market access, pricing strategies, and physician adoption in a field with multiple established and emerging therapies. The FDA’s review process and any potential advisory committee meeting will offer further insights into the agency’s perspective on this novel drug class. The outcome of this NDA will be a crucial bellwether for the broader field of PROTAC-based therapeutics.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
